Iza-bren (izalontamab brengitecan, BL-B01D1) is the world’s first approved EGFR × HER3 bispecific ADC. It binds both EGFR and HER3—two oncogenic receptors highly abundant in multiple epithelial cancers that fuel cancer growth and survival signals.

Iza-bren outperformed standard chemotherapy by significantly extending patients’ PFS and OS with clinically meaningful benefits. Its manageable safety profile validates it as a new standard treatment for heavily pre-treated late-stage nasopharyngeal carcinoma patients.

EGFR and HER3 are commonly co-expressed and functionally interact on solid tumor cells, allowing cancers to escape single-target therapy via compensatory signaling pathways. Iza-bren (Izalontamab brengitecan, BL-B01D1) is a first-in-class EGFR×HER3 bispecific ADC constructed with a dual-target antibody, tumor-specific cleavable linker and novel Topo-I inhibitor payload Ed-04.
Its dual mechanism acts in two layers: it simultaneously blocks both EGFR and HER3 growth signals to cut off tumor survival pathways; after internalization into cancer cells, the released toxin induces tumor cell death, plus robust bystander killing effect eliminates surrounding tumor cells and reduces resistance risks.

It is approved for adult patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after at least two lines of systemic platinum-based chemotherapy plus PD-1/PD-L1 inhibitor therapy.